Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/strategies-to-reduce-relapse-after-allogeneic-hematopoietic-cell-DFWlxMo3QS
References (62)
-
E. Alyea, D. DeAngelo, Jeffrey Moldrem, J. Pagel, D. Przepiorka, Michel Sadelin, James Young, S. Giralt, M. Bishop, S. Riddell (2010)
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 16 8
-
J. Scandura, G. Roboz, Michelle Moh, E. Morawa, F. Brenet, J. Bose, Luis Villegas, Usama Gergis, Sebastian Mayer, Cindy Ippoliti, T. Curcio, Ellen Ritchie, Eric Feldman (2011)
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.Blood, 118 6
-
U. Hegenbart, D. Niederwieser, B. Sandmaier, M. Maris, J. Shizuru, H. Greinix, C. Cordonnier, B. Rio, A. Gratwohl, T. Lange, H. Al-Ali, B. Storer, D. Maloney, P. Mcsweeney, T. Chauncey, E. Agura, B. Bruno, R. Maziarz, F. Petersen, R. Storb (2006)
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
-
R. Clift, Buckner Cd, F. Appelbaum, S. Bearman, F. Petersen, L. Fisher, C. Anasetti, P. Beatty, W. Bensinger, K. Doney (1990)
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.Blood, 76 9
-
F. Baron, M. Maris, B. Sandmaier, B. Storer, M. Sorror, R. Diaconescu, A. Woolfrey, T. Chauncey, M. Flowers, M. Mielcarek, D. Maloney, R. Storb (2005)
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 9
-
Robert Collins, O. Shpilberg, W. Drobyski, D. Porter, S. Giralt, R. Champlin, S. Goodman, S. Wolff, W. Hu, C. Verfaillie, A. List, W. Dalton, N. Ognoskie, A. Chetrit, J. Antin, J. Nemunaitis (1997)
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 2
-
H. Naina, M. Patnaik, S. Harris (2009)
Anthracycline dose intensification in acute myeloid leukemia.The New England journal of medicine, 361 26
-
S. Faderl, F. Ravandi, Xuelin Huang, G. Garcia-Manero, A. Ferrajoli, Z. Estrov, G. Borthakur, S. Verstovsek, D. Thomas, M. Kwari, H. Kantarjian (2008)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.Blood, 112 5
-
Volker Mailänder, C. Scheibenbogen, E. Thiel, A. Letsch, I. Blau, U. Keilholz (2004)
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicityLeukemia, 18
-
J. Cortes, A. Perl, Catherine Smith, T. Kovacsovics, H. Dombret, H. Döhner, B. Steffen, A. Pigneux, P. Rousselot, J. Krauter, G. Martinelli, E. Estey, A. Burnett, A. Ho, N. Ifrah, Theo Witt, R. Corringham, J. James, D. Lilienfeld, E. Leo, G. Gammon, M. Levis (2011)
A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim ResultsBlood, 118
-
M. Sorror, B. Sandmaier, B. Storer, G. Franke, G. Laport, T. Chauncey, E. Agura, R. Maziarz, A. Langston, P. Hari, M. Pulsipher, W. Bethge, F. Sahebi, B. Bruno, M. Maris, A. Yeager, F. Petersen, L. Vindeløv, P. Mcsweeney, K. Hübel, M. Mielcarek, G. Georges, D. Niederwieser, K. Blume, D. Maloney, R. Storb (2011)
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.JAMA, 306 17
-
A. Ferrant, M. Labopin, F. Frassoni, H. Prentice, J. Cahn, D. Blaise, J. Reiffers, G. Visani, M. Sanz, M. Boogaerts, B. Löwenberg, N. Gorin (1997)
Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).Blood, 90 8
-
Ning Li, C. Matte-Martone, Hong Zheng, W. Cui, Srividhya Venkatesan, Hung Tan, J. McNiff, A. Demetris, D. Roopenian, S. Kaech, W. Shlomchik (2011)
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.Blood, 118 22
-
G Garcia-Manero, H Yang, C Bueso-Ramos (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA)) in patients with advanced leukemias and myelodysplastic syndromesBlood, 111
-
J. Byrd, K. Mrózek, R. Dodge, A. Carroll, C. Edwards, D. Arthur, M. Pettenati, S. Patil, K. Rao, M. Watson, P. Koduru, J. Moore, R. Stone, R. Mayer, E. Feldman, F. Davey, C. Schiffer, R. Larson, C. Bloomfield (2002)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).Blood, 100 13
-
M. Bueger, A. Bakker, J. Rood, F. Woude, E. Goulmy (1992)
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.Journal of immunology, 149 5
-
I. André-Schmutz, F. Deist, S. Hacein-Bey-Abina, E. Vitetta, J. Schindler, G. Chédeville, E. Vilmer, A. Fischer, M. Cavazzana‐Calvo (2002)
Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 studyThe Lancet, 360
-
A. Tsuboi, Y. Oka, H. Ogawa, O. Elisseeva, H. Tamaki, Y. Oji, E. Kim, T. Soma, T. Tatekawa, M. Kawakami, T. Kishimoto, H. Sugiyama (1999)
Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF).Leukemia research, 23 5
-
Tabershaw Ir, Lamm Sh (1977)
Benzene and leukaemia.The Lancet, 2
-
S. Faderl, F. Ravandi, Xuelin Huang, Xuemei Wang, E. Jabbour, G. Garcia-Manero, T. Kadia, A. Ferrajoli, M. Konopleva, G. Borthakur, J. Burger, J. Feliu, H. Kantarjian (2012)
Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patientsCancer, 118
-
M. Lima, S. Giralt, P. Thall, L. Silva, Roy Jones, K. Komanduri, T. Braun, Hoang Nguyen, R. Champlin, G. Garcia-Manero (2010)
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndromeCancer, 116
-
Manish Sharma, F. Ravandi, U. Bayraktar, Alexandre Chiattone, Q. Bashir, S. Giralt, Julianne Chen, M. Qazilbash, P. Kebriaei, M. Konopleva, M. Andreeff, J. Cortes, Deborah McCue, H. Kantarjian, R. Champlin, M. Lima (2011)
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 12
-
A. Jakubowski, T. Small, N. Kernan, H. Castro-Malaspina, N. Collins, G. Koehne, K. Hsu, M. Perales, G. Papanicolaou, M. Brink, R. O'reilly, James Young, E. Papadopoulos (2011)
T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 9
-
C. Schmid, M. Labopin, A. Nagler, M. Bornhäuser, J. Finke, A. Fassas, L. Volin, G. Gürman, J. Maertens, P. Bordigoni, E. Holler, G. Ehninger, E. Polge, N. Gorin, H. Kolb, V. Rocha (2007)
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 31
-
D. Porter, B. Levine, N. Bunin, E. Stadtmauer, S. Luger, S. Goldstein, A. Loren, J. Phillips, S. Nasta, A. Perl, S. Schuster, D. Tsai, A. Sohal, E. Veloso, S. Emerson, C. June (2006)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.Blood, 107 4
-
Elizabeth Burton, B. Wong, Jiazhong Zhang, B. West, G. Bollag, G. Habets, A. Galanis, Hoa Nguyen, Omotayo Arowojolu, Trivikram Rajhowa, M. Levis (2011)
The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,Blood, 118
-
S. Devine, S. Carter, R. Soiffer, M. Pasquini, P. Hari, A. Stein, H. Lazarus, C. Linker, E. Stadtmauer, E. Alyea, C. Keever-Taylor, R. O'reilly (2011)
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 9
-
K. Rezvani, A. Yong, S. Mielke, Behnam Jafarpour, B. Savani, R. Le, R. Eniafe, Laura Musse, C. Boss, R. Kurlander, A. Barrett (2011)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignanciesHaematologica, 96
-
M. Tallman, G. Dewald, S. Gandham, B. Logan, A. Keating, H. Lazarus, M. Litzow, J. Mehta, T. Pedersen, W. Pérez, J. Rowe, M. Wetzler, D. Weisdorf (2007)
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.Blood, 110 1
-
U. Keilholz, A. Letsch, A. Busse, A. Asemissen, S. Bauer, I. Blau, W. Hofmann, L. Uharek, E. Thiel, C. Scheibenbogen (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.Blood, 113 26
-
Jaebok Choi, Julie Ritchey, Julie Prior, Matthew Holt, W. Shannon, E. Deych, D. Piwnica-Worms, J. Dipersio (2010)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.Blood, 116 1
-
L. Luznik, P. O'Donnell, H. Symons, Allen Chen, M. Leffell, M. Zahurak, Ted Gooley, S. Piantadosi, M. Kaup, Richard Ambinder, C. Huff, W. Matsui, J. Bolaños-Meade, I. Borrello, Jonathan Powell, Elizabeth Harrington, S. Warnock, M. Flowers, R. Brodsky, B. Sandmaier, R. Storb, Richard Jones, E. Fuchs (2008)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 6
-
J. Wagner, J. Thompson, S. Carter, N. Kernan (2005)
Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trialThe Lancet, 366
-
Said Dermime, Dimitrios Mavroudis, Y. Jiang, N. Hensel, J. Molldrem, A. Barrett (1997)
Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantationBone Marrow Transplantation, 19
-
H. Kolb, A. Schattenberg, J. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, F. Rhee, J. Mittermueller, T. Witte, E. Holler, H. Ansari (1995)
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.Blood, 86 5
-
S. Solomon, S. Mielke, B. Savani, Aldemar Montero, Laura Wisch, R. Childs, N. Hensel, J. Schindler, V. Ghetie, S. Leitman, T. Mai, C. Carter, R. Kurlander, E. Read, E. Vitetta, A. Barrett (2005)
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.Blood, 106 3
-
D. Porter, E. Alyea, J. Antin, Marcos DeLima, E. Estey, J. Falkenburg, N. Hardy, N. Kroeger, J. Leis, J. Levine, D. Maloney, K. Peggs, J. Rowe, A. Wayne, S. Giralt, M. Bishop, K. Besien (2010)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 16 11
-
P. Paschka, G. Marcucci, A. Ruppert, K. Mrózek, Hankui Chen, R. Kittles, T. Vukosavljevic, D. Perrotti, J. Vardiman, A. Carroll, J. Kolitz, R. Larson, C. Bloomfield (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 24
-
B. Löwenberg, G. Ossenkoppele, W. Putten, H. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen‐Lavrencic, M. Lilienfeld-Toal, B. Biemond, E. Vellenga, M. Kooy, L. Verdonck, J. Beck, H. Döhner, A. Gratwohl, T. Pabst, G. Verhoef (2009)
High-dose daunorubicin in older patients with acute myeloid leukemia.The New England journal of medicine, 361 13
-
J. Magenau, H. Tobai, A. Pawarode, T. Braun, E. Peres, P. Reddy, C. Kitko, S. Choi, G. Yanik, D. Frame, Andrew Harris, H. Erba, Lisa Kujawski, K. Elenitoba-Johnson, Jennifer Sanks, Dawn Jones, S. Paczesny, J. Ferrara, J. Levine, S. Mineishi (2011)
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.Blood, 118 15
-
A. Al-Mawali, D. Gillis, P. Hissaria, I. Lewis (2008)
Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.American journal of clinical pathology, 129 6
-
S. Hewitt, S. Hamada, T. McDonnell, F. Rauscher, G. Saunders (1995)
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.Cancer research, 55 22
-
J. Pagel, T. Gooley, J. Rajendran, D. Fisher, W. Wilson, B. Sandmaier, D. Matthews, D. Matthews, H. Deeg, A. Gopal, P. Martin, R. Storb, O. Press, F. Appelbaum (2009)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Blood, 114 27
-
Emmes (2005)
Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial -
R. Walter, T. Gooley, B. Wood, F. Milano, M. Fang, M. Sorror, E. Estey, A. Salter, Emily Lansverk, J. Chien, A. Gopal, F. Appelbaum, J. Pagel (2011)
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 9
-
A. Pinto, M. Maio, V. Attadia, S. Zappacosta, R. Cimino (1984)
MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINEThe Lancet, 324
-
J. Bolaños-Meade, B. Smith, S. Gore, M. McDevitt, L. Luznik, E. Fuchs, Richard Jones (2011)
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 5
-
U. Popat, M. Lima, R. Saliba, P. Anderlini, B. Andersson, A. Alousi, C. Hosing, Y. Nieto, S. Parmar, I. Khouri, P. Kebriaei, M. Qazilbash, R. Champlin, S. Giralt (2012)
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CRBone Marrow Transplantation, 47
-
A. Jakubowski, T. Small, James Young, N. Kernan, H. Castro-Malaspina, K. Hsu, M. Perales, N. Collins, C. Cisek, M. Chiu, M. Brink, R. O'reilly, E. Papadopoulos (2007)
T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.Blood, 110 13
-
D. Kim, S. Sohn, Jong Kim, N. Lee, W. Sung, J. Baek, J. Suh, K. Lee, K. Lee (2004)
Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantationAnnals of Hematology, 84
-
C. Schmid, M. Schleuning, G. Ledderose, J. Tischer, H. Kolb (2005)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
-
U. Hegenbart, D. Niederwieser, B. Sandmaier, Michael Maris, J. Shizuru, H. Greinix, C. Cordonnier, B. Rio, A. Gratwohl, T. Lange, H. Al-Ali, B. Storer, D. Maloney, P. Mcsweeney, T. Chauncey, E. Agura, B. Bruno, R. Maziarz, F. Petersen, R. Storb (2006)
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated DonorsJournal of Clinical Oncology, 24
-
Yiming Chen, J. Cortes, Z. Estrov, S. Faderl, W. Qiao, L. Abruzzo, G. Garcia-Manero, S. Pierce, Xuelin Huang, P. Kebriaei, T. Kadia, M. Lima, H. Kantarjian, F. Ravandi (2011)
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 18
-
J. Levine, T. Braun, S. Penza, P. Beatty, K. Cornetta, R. Martino, W. Drobyski, A. Barrett, D. Porter, S. Giralt, J. Leis, H. Holmes, Matthew Johnson, M. Horowitz, R. Collins (2002)
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 2
-
S. Metzelder, Ying Wang, E. Wollmer, M. Wanzel, Sabine Teichler, A. Chaturvedi, M. Eilers, E. Enghofer, A. Neubauer, A. Burchert (2009)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.Blood, 113 26
-
S. Coral, L. Sigalotti, A. Gasparollo, I. Cattarossi, A. Visintin, A. Cattelan, M. Altomonte, M. Maio (1999)
Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).Journal of immunotherapy, 22 1
-
G. Alatrash, M. Lima, N. Hamerschlak, M. Pelosini, Xuemei Wang, Lianchun Xiao, F. Kerbauy, Alexandre Chiattone, G. Rondon, M. Qazilbash, S. Giralt, L. Silva, C. Hosing, P. Kebriaei, Weiqing Zhang, Y. Nieto, R. Saliba, R. Champlin, B. Andersson (2011)
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 10
-
G. Kobbe, R. Fenk, Frank Neumann, A. Bernhardt, U. Steidl, M. Kondakci, Thorsten Graef, M. Aivado, Matthias Vaupel, Ali-Nuri Huenerlituerkoglu, R. Kronenwett, H. Pape, Barbara Hildebrand, U. Germing, R. Haas (2004)
Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.Cytotherapy, 6 6
-
B. Andersson, B. Valdez, M. Lima, Xuemei Wang, P. Thall, L. Worth, U. Popat, T. Madden, C. Hosing, A. Alousi, G. Rondon, P. Kebriaei, E. Shpall, Roy Jones, R. Champlin (2011)
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 6
-
Y. Linn, Y. Goh, H. Tan (2000)
Relapse of Leukemia and Lymphoma after Marrow Transplant: A Review of Cases with Extramedullary RelapseLeukemia & Lymphoma, 38
-
J. Pagel, F. Appelbaum, J. Eary, J. Rajendran, D. Fisher, T. Gooley, K. Ruffner, Eneida Nemecek, Eileen Sickle, L. Durack, J. Carreras, M. Horowitz, O. Press, A. Gopal, P. Martin, I. Bernstein, D. Matthews (2006)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.Blood, 107 5
-
M Lima, S Giralt, PF Thall (2010)
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding studyCancer, 116
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0153-6
- pmid
- 23456518
- Publisher site
- See Article on Publisher Site
Abstract
The incidence of acute myeloid leukemia (AML) is expected to increase in conjunction with our ageing population. Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. Although this is presumed to be a curative strategy, many patients relapse after transplant, prompting us to examine various ways that we can improve outcomes. These efforts involve every step of AML diagnostics and therapy, including the intricate processes of conditioning, graft manipulation and immunomodulation. The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Mar 3, 2013